Guest User 12/6/22 Guest User 12/6/22 Medikine Appoints Roland Buelow, Ph.D., to Board of Directors Read More Lara Wilson 11/10/22 Lara Wilson 11/10/22 Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7) Read More Lara Wilson 10/5/22 Lara Wilson 10/5/22 Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) Read More Lara Wilson 7/19/22 Lara Wilson 7/19/22 Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development Read More Lara Wilson 4/6/22 Lara Wilson 4/6/22 Medikine to Highlight Preclinical Data on its Lead Program MDK-703, an IL-7 Mimetic, at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) Read More
Guest User 12/6/22 Guest User 12/6/22 Medikine Appoints Roland Buelow, Ph.D., to Board of Directors Read More
Lara Wilson 11/10/22 Lara Wilson 11/10/22 Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7) Read More
Lara Wilson 10/5/22 Lara Wilson 10/5/22 Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) Read More
Lara Wilson 7/19/22 Lara Wilson 7/19/22 Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development Read More
Lara Wilson 4/6/22 Lara Wilson 4/6/22 Medikine to Highlight Preclinical Data on its Lead Program MDK-703, an IL-7 Mimetic, at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) Read More
